A number of strategies are under development by various groups for the creation of therapeutic tumor vaccines using gene transfer in autologous tumor cells. However, gene transfer entails a number of technical problems that limit both the clinical utility and commercial viability of such vaccines. As an alternative, this project will identify a chimeric GPI-linked molecule that improves the efficiency of events in the afferent limb of the immune response. The utility of this molecule in the creation of tumor vaccines will be tested in mouse models.

Proposed Commercial Applications

Novel technology for cancer vaccines

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA086650-01
Application #
6143080
Study Section
Special Emphasis Panel (ZRG1-SSS-4 (02))
Program Officer
Muszynski, Karen
Project Start
2000-03-01
Project End
2001-10-31
Budget Start
2000-03-01
Budget End
2001-10-31
Support Year
1
Fiscal Year
2000
Total Cost
$204,019
Indirect Cost
Name
Genitrix, LLC
Department
Type
DUNS #
969875491
City
Cambridge
State
MA
Country
United States
Zip Code
02142